News >

Targeted Agents Continue to Advance in MCL, With CAR T on the Horizon

Caroline Seymour
Published: Tuesday, Sep 24, 2019

Dr. Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD

Several drugs have been developed in the lymphoid space in recent years, including BTK inhibitors and BCL-2 inhibitors, which have shown significant activity in mantle cell lymphoma (MCL), said Andrew D. Zelenetz, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication